Gefitinib (ZD1839) (INN, /ɡɛˈfɪtᵻnɪb/, trade name Iressa) is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR. It is marketed by AstraZeneca and Teva.
Product Detailed
Name: Gefitinib
CAS No.: 184475-35-2
Formula: C22H24ClFN4O3
Molecular Weight: 446.90 .
Synonyms:N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;ZD1839;4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline;Irressat;Gefitinib (JAN/USAN);4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;
Density: 1.322 g/cm3
Melting Point: 119-120 °C
Boiling Point: 586.8 °C at 760 mmHg
Flash Point: 308.7 °C
Appearance: light-yellow crystalline powder
| Product name | Gefitinib |
| CAS NO. | 184475-35-2 |
| Description | White or almost white powder |
| Melting point | 188°C~193°C |
| Loss on drying | £1.0% |
| Residue on ignition | £0.1% |
| Assay | ≥99.0% |
SPECIFICATIONS:
| ITEMS | SPECIFICATIONS | RESULTS |
| Description | Slight white to white crystalline powder | White crystalline powder |
| Identification(IR) | Conforms to the reference | Cnforms to th reference |
| Melting piont | 194.0~198.0℃ | 195.5~197.0℃ |
| Water (KF) | 0.30% | 0.21% |
| Individual purity | 0.50% | 0.15% |
| Assay (HPLC) | 99% | 99.28% |
| Conclusion | Complies with Enterprise standard | |
Packing and storage:
Storage: Store in cool & dry place, Keep away from strong light and heat.
Shelf life: 24 Months when properly stored.
Packing: Paper-drums for outer and two plastic-bags inside
N.W.: 25 kgs
G.W.:28 kgs
Delivery: within two weeks after receiving your prepayment.
没有评论:
发表评论